Pharmaceutical and Biopharmaceutical sciences continue to find new applications, new modalities and a new class of compounds that can improve life expectancy and standards of living for people affected by chronic or degenerative diseases. Mr. Aldo Braca, the founder of BSP Pharmaceuticals speaks with IPI explaining how BSP expects this trend to continue and how the group will consolidate and expand, offering the highest level of services and technology necessary to produce those innovative drugs.
‘At the Forefront of Innovative Therapeutic Excellence Since 2006’
Mr. Aldo Braca, the fonder and CEO of BSP Pharmaceuticals speaks with IPI explains how BSP will consolidate and expand offering the highest level of services and technology necessary to produce innovative drugs.
Q: BSP Pharmaceuticals has been at the forefront of the fight against cancer since 2006. Can you tell our readers the brief history of the company, how the company started and your growth so far?
A: BSP was created with the mission to become a valuable and trustable partner for innovators, engaged in the research of new effective therapies against cancer. Our original focus was on small molecules. Mostly used in classic chemotherapy, but very soon, with the objective of supporting innovative therapies, we also found ourselves engaged in manufacturing biological large molecules as they were more promising innovative products for new generation of oncology therapies.
After successful results and receiving certification of our quality system, we were capable to meet requirements of the most demanding regulatory agencies, our growth has been driven by the increased demand of capacity for Oncology products (that was mainly planned as part of the intelligence work at the beginning of the project) and by the strategic decision to strongly support the development and evolution of ADCs and oncology biological derivatives.
Operating world class technology, paying attention to market demand and subsequently investing to expand available capacity which could be offered to partners, have been the most important hallmark of BSP.
Now the company has a consolidated role in supplying anticancer products and is a reference for ADCs scientific community and is ready to initiate a new step in its history by opening capacity for additional therapeutic areas.
Click the download button below to read the complete version of ‘At the Forefront of Innovative Therapeutic Excellence Since 2006′ by Mr. Aldo Braca, the founder of BSP Pharmaceuticals